Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.72 |
| ▸ | KIT | P10721 | 10/20 | 0.72 |
| ▸ | KDR | P35968 | 9/20 | 0.72 |
| ▸ | MAPK9 | P45984 | 7/20 | 0.72 |
| ▸ | LCK | P06239 | 6/20 | 0.72 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.45 |
| ▸ | LYN | P07948 | 1/20 | 0.43 |
| ▸ | PDE7A | Q13946 | 4/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2944221 | 0.88 | MAPK14 (0.69) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL2945618 | 0.83 | MAPK14 (1.00) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL2956864 | 0.81 | MAPK14 (0.95) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL2945941 | 0.80 | MAPK14 (0.81) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL2953959 | 0.80 | MAPK14 (0.81) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL2945648 | 0.79 | MAPK14 (1.00) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL2945950 | 0.77 | MAPK14 (0.81) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL2952386 | 0.75 | MAPK14 (0.81) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL2945875 | 0.74 | MAPK14 (0.84) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL2944127 | 0.74 | MAPK14 (0.80) | MAPK14KITKDRMAPK9LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856058-B1 | PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2014-09-03 | — | — | EP | disclosed |
| US-7759337-B2 | Phthalazine compounds and methods of use | AMGEN INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-20060199817-A1 | Phthalazine, aza- and diaza-phthalazine compounds and methods of use | AMGEN INC. (US) | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199817-A1 | Phthalazine, aza- and diaza-phthalazine compounds and methods of use | DAPK2, CDK2, DAPK1 | MAPK14 293/4885KIT 1977/4885KDR 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.